Institutional members access full text with Ovid®

Share this article on:

The Oviduct and Ovarian Cancer: Causality, Clinical Implications, and “Targeted Prevention”

CRUM, CHRISTOPHER P. MD*,†; MCKEON, FRANK D. PhD*,†; XIAN, WA PhD*,†

Clinical Obstetrics and Gynecology: March 2012 - Volume 55 - Issue 1 - p 24–35
doi: 10.1097/GRF.0b013e31824b1725
Ovarian Cancer

A novel origin for pelvic serous cancer (ovarian cancer) has been proposed in the distal oviduct. This has important implications, including both early detection in high-risk women and wisdom of relying on serological tests to detect a disease that begins so close to the peritoneal surfaces. With the recent discovery of premalignant disturbances in gene function in the tubal mucosa, the concept of targeted prevention is emerging whereby the interruption of a portion of the carcinogenic pathway will prevent cancer. This alternative to detect early malignancy is a new paradigm in the quest to prevent this deadly disease.

*Department of Pathology, Division of Women’s and Perinatal Pathology, Brigham and Women’s Hospital, Department of Cell Biology, Harvard Medical School, Boston, Massachusetts;

Genome Institute of Singapore, A-Star, Singapore, Singapore

The authors declare that they have nothing to disclose.

Correspondence: Christopher P. Crum, MD, Department of Pathology, Division of Women’s and Perinatal Pathology, Brigham and Women’s Hospital, Boston, MA. E-mail: ccrum@partners.org

© 2012 Lippincott Williams & Wilkins, Inc.